Vistim Labs

Miami, FloridaFounded 20211–10 employeesvistimlabs.comLinkedIn

Founded: 2021
Employees: 1–10

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

Vistim Labs’ documented milestones center on early financing and participation in digital-health programs rather than a sustained stream of company-specific announcements. On Jul 12, 2022, the company was identified as a graduate of the PharmStars spring accelerator, linking its work to a pharma-focused commercialization network. PharmStars also provided non-equity assistance dated Jul 12, 2022, although no amount is disclosed. On Mar 1, 2023, Vistim Labs closed a $807,000 seed round led by GoAhead Ventures, with Beresford Ventures and RK Hart Capital also participating. The company subsequently received a $10,000 grant from Alberta Innovates on Jun 8, 2023. Its stated clinical focus is neurological-disorder detection, treatment support, and longitudinal tracking, with products spanning dementia evaluation, functional assessment, and CASBA (JH-Flicker). Website positioning adds Ceregram, described as a routine, radiation-free, in-clinic monitoring solution. This limits confidence about commercial adoption, regulatory progress, and activity since mid-2023.

Market position

Vistim Labs operates at the intersection of neurological diagnostics, medical devices, digital health, and neuroscience. Its proposed differentiation is the combination of non-invasive monitoring with software that interprets visuospatial deficits and EEG-derived patient data. The company describes applications including dementia assessment, estimation of amyloid and tau-related clinical endpoints, brain-volume atrophy analysis, treatment-response monitoring, and support for clinical-study enrollment. The most relevant competitive groups are likely neurological imaging providers, EEG and neurophysiology platforms, digital cognitive-assessment companies, and biomarker-focused diagnostic developers. Vistim’s $807,000 seed round and team profile indicate an early-stage position rather than scaled market leadership.

Growth & opportunities

Vistim Labs shows an early development trajectory supported by program participation, seed financing, and a subsequent grant. The first documented milestone is PharmStars non-equity assistance on Jul 12, 2022, alongside participation in the spring 2022 accelerator cohort. That milestone suggests an initial effort to translate a neurological diagnostic concept toward pharmaceutical and clinical-research use cases. The company then reached its clearest financing inflection point on Mar 1, 2023, raising $807,000 in seed funding led by GoAhead Ventures and joined by Beresford Ventures and RK Hart Capital. A $10,000 Alberta Innovates grant followed on Jun 8, 2023, bringing disclosed funding to $817,000 across three rounds. Product breadth includes Dementia Evaluation Software, a Functional Assessment Tool, and CASBA (JH-Flicker), while the company’s website highlights Ceregram for routine, radiation-free monitoring. The available employee range remains one to ten people, and no hiring expansion, layoffs, later financing, launch, or revenue milestone is documented. Accordingly, the trajectory indicates technical and clinical development progress through mid-2023, but not yet evidence of scaled commercialization through Oct 7, 2026.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes Vistim Labs distinct

reccy insights

What makes Vistim Labs distinct

01Provides routine, radiation-free monitoring in a clinical setting.
02Focuses on improving patient outcomes through ongoing neurological monitoring.
03Combines expertise in neurology, neuroscience, medical devices, artificial intelligence, and clinical development.
04Applies translational biomarker and data-science expertise to neurological assessment.
05Draws on advisors with experience commercializing medical products, diagnostics, and pharmaceuticals.

Technology & products3

Technology & products

Dementia Evaluation Software
AI software for evaluating dementia using visuospatial deficits measured via EEG, comparing patient data to estimate clinical endpoints such as amyloid and tau protein presence and brain-volume atrophy.
Functional Assessment Tool
A non-invasive, portable AI platform for showing how treatments affect symptomatic onset of neurodegenerative diseases, supporting study enrollment and intervention assessment.
CASBA (JH-Flicker)
Technology for clinical research that evaluates visuospatial deficits across Alzheimer’s, schizophrenia, and other indications, with reported predictive applications involving amyloid uptake values and cognitive assessments.

About Vistim Labs

Products: Dementia Evaluation Software, Functional Assessment Tool, CASBA (JH-Flicker)
Leadership: James Hamet
Focus areas: Digital health, medical devices, neurology, neuroscience, patient monitoring, clinical diagnostics, healthcare technology, radiation free monitoring
Headquarters: Miami, Florida
Founded: 2021
Employees: 1–10